Independent Advisor Alliance grew its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 5.9% during the 3rd quarter, Holdings Channel reports. The firm owned 106,213 shares of the company’s stock after purchasing an additional 5,953 shares during the period. Johnson & Johnson makes up approximately 0.7% of Independent Advisor Alliance’s portfolio, making the stock its 21st biggest position. Independent Advisor Alliance’s holdings in Johnson & Johnson were worth $28,454,000 as of its most recent SEC filing.
Several other hedge funds have also recently bought and sold shares of the stock. Meeder Asset Management Inc. increased its stake in Johnson & Johnson by 26.9% in the 3rd quarter. Meeder Asset Management Inc. now owns 148,668 shares of the company’s stock valued at $39,358,000 after buying an additional 31,476 shares during the last quarter. MA Private Wealth raised its position in Johnson & Johnson by 15.7% during the third quarter. MA Private Wealth now owns 1,633 shares of the company’s stock valued at $432,000 after purchasing an additional 222 shares in the last quarter. Baron Silver Stevens Financial Advisors LLC lifted its stake in shares of Johnson & Johnson by 1.4% in the 3rd quarter. Baron Silver Stevens Financial Advisors LLC now owns 5,324 shares of the company’s stock valued at $1,410,000 after acquiring an additional 71 shares during the last quarter. Everest Private Wealth grew its stake in shares of Johnson & Johnson by 5.8% in the third quarter. Everest Private Wealth now owns 1,523 shares of the company’s stock worth $403,000 after purchasing an additional 83 shares during the last quarter. Finally, Chancellor Financial Group WB LP raised its stake in Johnson & Johnson by 2.1% during the third quarter. Chancellor Financial Group WB LP now owns 16,717 shares of the company’s stock worth $4,426,000 after buying an additional 344 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.
Insider Buying and Selling at Johnson & Johnson
In related news, EVP Timothy Schmid sold 33,597 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the sale, the executive vice president owned 25,447 shares in the company, valued at $6,991,308.78. This trade represents a 56.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Elizabeth Forminard sold 13,072 shares of Johnson & Johnson stock in a transaction on Thursday, November 12th. The stock was sold at an average price of $284.39, for a total value of $3,717,546.08. Following the transaction, the executive vice president directly owned 16,994 shares of the company’s stock, valued at approximately $4,832,923.66. This represents a 43.48% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Company insiders own 0.16% of the company’s stock.
Latest Johnson & Johnson News
Here’s some of the latest news about JNJ:
- Positive Sentiment: J&J submitted an FDA application to expand CAPLYTA’s use to manic or mixed episodes associated with bipolar I disorder. Two Phase 3 trials showed symptom improvement versus placebo; approval would add a potential fifth adult indication and broaden the drug’s commercial opportunity. Article: Johnson & Johnson Seeks U.S. FDA Approval for CAPLYTA
- Negative Sentiment: A Louisiana appeals court upheld a multimillion-dollar mesothelioma verdict against J&J related to talc in its baby powder, renewing concern about litigation exposure. Article: Louisiana Appeals Court Upholds Damages in Mesothelioma Case
- Negative Sentiment: Recent coverage also associated a prior decline in JNJ shares with insider selling, which can add near-term pressure on investor sentiment. Article: JNJ Stock Price Down Following Insider Selling
Wall Street Analysts Forecast Growth
A number of equities analysts have recently weighed in on JNJ shares. Leerink Partners cut their target price on Johnson & Johnson from $276.00 to $272.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 14th. Wells Fargo & Company upped their price target on shares of Johnson & Johnson from $275.00 to $287.00 and gave the company an “overweight” rating in a research report on Friday, October 16th. Erste Group Bank lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Wednesday, October 21st. Citigroup upped their target price on shares of Johnson & Johnson from $298.00 to $303.00 and gave the stock a “buy” rating in a research note on Monday, October 5th. Finally, Morgan Stanley dropped their price objective on shares of Johnson & Johnson from $294.00 to $292.00 and set an “overweight” rating on the stock in a report on Thursday, October 15th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $275.92.
View Our Latest Stock Analysis on Johnson & Johnson
Johnson & Johnson Trading Down 2.1%
Johnson & Johnson stock opened at $272.75 on Thursday. The firm has a market cap of $656.58 billion, a PE ratio of 41.33, a P/E/G ratio of 2.75 and a beta of 0.22. Johnson & Johnson has a 12 month low of $199.38 and a 12 month high of $290.25. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 0.44. The stock’s 50 day simple moving average is $267.42 and its two-hundred day simple moving average is $250.61.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The firm had revenue of $25.40 billion for the quarter, compared to the consensus estimate of $25.38 billion. During the same period last year, the firm posted $2.80 earnings per share. The company’s revenue for the quarter was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Analysts anticipate that Johnson & Johnson will post 11.12 earnings per share for the current year.
Johnson & Johnson Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be given a dividend of $1.34 per share. The ex-dividend date is Tuesday, November 24th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.0%. Johnson & Johnson’s payout ratio is 81.21%.
Johnson & Johnson Company Profile
Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.
Read More
- Five stocks we like better than Johnson & Johnson
- Target Stock Is Up Over 70%—Has the Easy Money Already Been Made?
- Amazon’s Zoox Just Joined Uber—Could That Change the Robotaxi Threat?
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
